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ABSTRACT 14 
The 16S rRNA binding mechanism proposed for the antibacterial action of the tetracyclines does not 15 
explain their mechanism of action against non-bacterial pathogens. Also, several contradictory base 16 
pairs have been proposed as their binding sites on the 16S rRNA. This study investigated the binding 17 
of minocycline and doxycycline to short dsRNAs of random base sequences. These tetracyclines 18 
caused a dose-dependent decrease in the fluorescence intensities of FAM-labelled dsRNA and EtBr 19 
stained dsRNA, indicating that both drugs bind to dsRNA of random base sequence in a manner that 20 
is competitive with the binding of ethidium bromide and other nucleic acid ligands often used as 21 
stains. This effect was observable in the presence of Mg
2+
. The binding of the tetracyclines to dsRNA 22 
changed features of the fluorescence emission spectra of the drugs and the circular dichroism spectra 23 
of the RNA, and inhibited RNase III cleavage of the dsRNA. These results indicate that the double-24 
stranded structures of RNAs may play a more important role in their interaction with the tetracyclines 25 
than the specific base pairs which had hitherto been the subject of much investigation. Given the 26 
diverse functions of cellular RNAs, the binding of the tetracyclines to their double-stranded helixes 27 
may alter the normal processing and functioning of the various biological processes they regulate. 28 
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This could help to explain the wide range of action of the tetracyclines against various pathogens and 29 
disease conditions. 30 
Keywords: Double-stranded RNA, minocycline, doxycycline, mechanism of action, drug binding, 31 
molecular interactions. 32 
1. INTRODUCTION 33 
The tetracyclines are a group of broad-spectrum antibiotics that are known to act by inhibiting the 34 
binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis 
1,2
. 35 
They are generally believed to bind to the 16S ribosomal RNA, which is composed of a 1540 36 
nucleotide RNA. In addition to their use as antibacterial agents, the tetracyclines are also known to be 37 
effective in the treatment of non-bacterial infections e.g. in the treatment of protozoan diseases such 38 
as giardiasis 
3
, and viral diseases such as West Nile fever 
4
. They also possess anti-inflammatory 
5,6
, 39 
anti-apoptotic 
7
 and neuroprotective properties 
8
.There is little indication of the mechanism(s) of 40 
action that underlie many of the reported activities 
5,9,10
. Because of the similarities between the 41 
bacterial ribosome and mitochondrial ribosome, it was believed that the anti-protozoal activities of the 42 
tetracyclines were mediated via a similar interaction with the mitochondrial ribosome of these 43 
parasites 
11
. However, the susceptibility of other protozoan species which lack mitochondria (e.g. 44 
Trichomonasvaginalis, Giardia lamblia, Entamoebahistolytica) 
1,3
, as well as viruses and helminths 45 
raises further questions about the exact target site(s) and molecular mechanism(s) of action of the 46 
tetracyclines. 47 
Several studies have explored the binding of the tetracyclines to the small ribosomal subunit of 48 
different bacterial species with a view to identifying the exact target site 
12
. A number of binding sites 49 
have been identified on the 16S rRNA through photoaffinity labelling and chemical footprinting, 50 
indicating certain bases as contributing to the binding pocket 
13-15
. However, there have been varied 51 
and sometimes conflicting reports with regards to which bases within the 16S rRNA form the core 52 
target site(s) 
14,16
. It has been reported that tetracyclines induce stabilization of various cellular 53 
mRNAs in bacteria, indicating a more generalised interaction/effect on RNA 
17
. Interestingly, the 54 
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viruses against which the tetracyclines have shown some efficacy are RNA viruses (e.g. West Nile 55 
fever virus 
7
, Japanese encephalitis virus 
18
,human immunodeficiency virus 
19-21
). Bearing in mind 56 
that the 16S ribosomal RNAs (like most cellular RNAs) fold to form double-stranded secondary 57 
structures which are potential sites for interaction with small molecules 
22,23
; and that the flat 58 
polycyclic structure and size of the tetracyclines confers potential for intercalation between base pairs 59 
of nucleic acids, the binding of the tetracyclines to dsRNA is worth considering as a possible target 60 
site on the 16S rRNA (other than the proposed conflicting base pairs) that could allow the drugs bind 61 
to and act against microbes that lack the 16S ribosomal RNA (such as viruses and some protozoa). If 62 
such binding exists irrespective of the RNA base pairs (which is highly conserved in bacterial rRNA), 63 
it could account for the wide range of action of the tetracyclines. In this study, the interactions of 64 
minocycline (C23H27N3O7) and doxycycline (C22H24N2O8) with short double stranded RNAs of 65 
random base sequences were investigated, with a view to identifying the nature and essential elements 66 
of their interactions. 67 
 68 
2. MATERIALS AND METHODS 69 
Nucleic acids used in this study include a small interfering RNA (siRNA) labelled with 6-70 
carboxyfluorescein (FAM-labelled dsRNA), 27 base pair RNA/DNA 1 and 2 formed from randomly 71 
selected complementary base sequences (5’-cauucgcaugaugccagugguacuaac-3’), and poly I:C. FAM-72 
labelled dsRNA (siGLO® transfection indicator siRNA) was purchased from Thermo Fisher 73 
Scientific (Dharmacon #D-001630-01-05). The rest were synthesized by Sigma® Aldrich. 27bp 74 
RNA/DNA 1 and 2 were reconstituted to 100µM stock solution in 1x PBS, and aliquots stored at -75 
20
o
C. To obtain the unlabelled 27bp dsRNA and dsDNA, equal volumes of the complementary single 76 
strand stock solutions were mixed, then heated to 65
o
C for 5mins to denature any secondary structures 77 
formed during storage, and allowed to cool slowly to enhance efficient annealing. Aliquots of the 78 
27bp dsRNA and dsDNA were then stored at -20
o
C. Radio-labelled 27bp dsRNA was obtained by 79 
labelling one strand of the 27bp RNA with 
32
P (to a final concentration of 100nM) using Adenosine 80 
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5’-triphosphate [γ-32P] (PerkinElmer) and T4 Polynucleotide Kinase (Fermentas) according to 81 
manufacturer’s instructions. The radio-active strand was then washed with QIAquick nucleotide 82 
removal kit and kept at 4
o
C. It was subsequently annealed with the complementary strand just before 83 
use. Minocycline, doxycycline and magnesium sulphate were also purchased from Sigma® Aldrich. 84 
Adenosine 5’-triphosphate [γ-32P] for radioactive labelling was obtained and T4 Polynucleotide 85 
Kinase. Nucleotide removal was done with QIAquick nucleotide removal kit (QIAGEN #28304). All 86 
buffers and reagent solutions for experiments involving RNA were reconstituted in DEPC-treated 87 
water to inactivate RNases. 88 
2.1. Gel electrophoresis binding studies 89 
The interaction of minocycline and doxycycline with dsRNA was studied by gel electrophoresis using 90 
either 1% agarose gels in 1X TBE or 10% native polyacrylamide gel 
24,25
.The effect of this interaction 91 
on dsRNA band intensity was initially investigated with 200nM FAM-labelled dsRNA in 1X 92 
NEBuffer 2 (New England Biolabs), which contains 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 93 
1 mM Dithiothreitol, pH 7.9 at 25°C. After Mg
2+
 was identified as the critical component of the buffer 94 
for an observable effect on band intensity, subsequent experiments were performed with unlabelled 95 
random 27bp dsRNA (500nM) in 0.5x PBS + 5mM MgSO4. For these experiments, a range of 96 
concentrations of minocycline or doxycycline (0-1000µM) were added to 1.5 ml microcentrifuge 97 
tubes containing the dsRNA in buffer. The mixtures were incubated for 15-30 min at room 98 
temperature before loading in the gel. Binding competition assays were done by adding 1X EtBr 99 
(0.5µg/ml ethidium bromide, ≈1.27µM) into the sample either before or after adding 100 
minocycline/doxycycline. Electrophoresis was performed at 5v/cm in 0.5X TBE (30V for 90mins 101 
using Bio-Rad PowerPac and electrophoresis apparatus). For gel mobility shift assays 
26
, 102 
electrophoresis was done using fine resolution gel (10% native polyacrylamide gels) that would detect 103 
small differences in migration undetectable with agarose gels, and running the gel for longer (3-4hrs 104 
at 150V) to ensure adequate separation of the bands. When unlabelled dsRNA were used in the 105 
samples, gels were stained with EtBr (unless otherwise stated) by soaking the gels in 1x EtBr solution 106 
(0.5µg/ml) for 15-20mins after electrophoresis and destained in distilled water for 10mins. Images 107 
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were captured using SynGene G:Box camera and GeneSnap image software. For experiments 108 
involving radio-labelled dsRNA, the concentration of minocycline or doxycycline and dsRNA used 109 
were proportionately reduced from the concentrations used for the FAM-labelled and EtBr-stained 110 
experiments to acceptable levels for working safely with radioactivity (5nM dsRNA and 0-10 µM 111 
minocycline/doxycycline). Samples were incubated at 37
o
C for 30mins before loading in wells of 112 
10% native acrylamide gel. Gels were dried in a gel dryer after electrophoresis and exposed in a film 113 
cassette overnight. Images were taken with a Fujifilm image reader (FLA-3000 series v1.8) and 114 
analysed using Multiguage v3.0 image software. 115 
2.2. Fluorescence spectroscopy 116 
The changes in the absorbance and fluorescence emission spectra of minocycline/doxycycline upon 117 
binding to RNA were studied by fluorescence spectroscopy 
27-29
. A range of concentrations of both 118 
dsRNA (0-20µM) and minocycline/doxycycline (0-500μM) in Tris buffer (pH 8) + 5mM MgSO4 119 
were used in a 96 well plate. The absorbance and fluorescence emission spectra of the samples were 120 
monitored using a SpectraMax M2 microplate reader operated with SOFTmax PRO data collection 121 
software. The optimal excitation wavelength of minocycline/doxycycline was first determined by 122 
measuring the absorbance and excitation spectra. The fluorescence emission spectra were 123 
subsequently monitored with the excitation wavelength fixed at the pre-determined maximum 124 
absorption wavelength. 125 
2.3. Circular dichroism 126 
The binding of the tetracyclines to dsRNA was also studied by circular dichroism as described by 127 
Khan and Musarrat 2003 
28,30
 using poly I:C titrated against a range of concentrations of 128 
minocycline/doxycycline (0-50µM). The CD spectra of a fixed concentration of poly I:C (50µM) was 129 
first obtained, as well as that of the highest concentrations of minocycline and doxycycline used. The 130 
fixed concentration of poly I:C was then titrated against increasing concentrations of the drugs and the 131 
CD spectra of the dsRNA upon interaction with the given concentrations of minocycline or 132 
doxycycline was recorded. 133 
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2.4. RNase protection assay 134 
The effect of doxycycline on RNase III cleavage and consequent degradation of dsRNA was studied 135 
by using ShortCut® RNase III to digest 27bp dsRNA in the absence and presence of 1mM 136 
doxycycline following the manufacturer’s protocol. Samples were collected from the reaction mixture 137 
at given time points. Upon sample collection, the reaction was stopped by transferring collected 138 
samples to tubes containing 5X EDTA on ice before loading in 1% agarose gels. Electrophoresis was 139 
carried out at 30V for 120mins, and the gels were stained with ethidium bromide (EtBr). Images were 140 
taken with SynGene G:Box camera using GeneSnap image software. 141 
2.5. Data Analysis 142 
RNA bands were quantified using the image processing software, GeneTools from SynGene. 143 
Statistical analysis (multiple regression) was done using IBM SPSS Statistics version 19. 144 
 145 
3. RESULTS  146 
3.1. Effects of the tetracyclines on fluorescence intensity of dsRNA bands  147 
Agarose gel electrophoresis of FAM-labelled dsRNA to which a range of concentrations of 148 
minocycline or doxycycline had been added showed a decrease in the fluorescence intensity of the 149 
dsRNA bands with increasing amounts of minocycline or doxycycline (Figure 1A). This indicates 150 
some kind of interaction between the tetracyclines and dsRNA. To investigate the nature of these 151 
interactions, the experiments were repeated using the non-labelled 27bp dsRNA of random sequence, 152 
and the gel was stained with EtBr after electrophoresis. Again, there was decreasing band intensity 153 
with increasing concentration of tetracycline (Figure 1B). The observed decrease in band intensity of 154 
dsRNA with increasing concentrations of tetracycline appears similar to the band intensity of lower 155 
amounts of dsRNA  in the absence of the tetracyclines (Figure 1C). This suggests that the interaction 156 
of the tetracyclines with dsRNA effectively reduces the amounts of dsRNA (binding sites) available 157 
8 
 
for EtBr binding in the samples during staining, even though the same amount of dsRNA was used in 158 
these samples. 159 
3.2. The effects of Mg2+ on the binding of the tetracyclines to dsRNA 160 
When the previous experiments involving FAM-labelled dsRNA were conducted with water or PBS 161 
in place of NEBuffer 2, there was no observable effect of tetracycline on the band intensity. Hence, 162 
the component of the buffer essential for the observed effect on band intensity was investigated. 163 
When the experiments were conducted in PBS buffer in the absence or presence of increasing 164 
concentrations of Mg
2+
, the gel showed decreasing dsRNA band intensity with increasing 165 
concentration of minocycline or doxycycline in the samples that contain Mg
2+
. This decrease in 166 
dsRNA band intensity was obscure in the absence of Mg
2+
, and was enhanced with increasing 167 
concentrations of Mg
2+
 (Figure 2). Similar results were also obtained for minocycline. These results 168 
indicate that Mg
2+
 enhances the interaction of the tetracyclines with dsRNA. In the samples containing 169 
doxycycline, a diffuse fluorescence increasing in a dose-dependent manner was observed above the 170 
dsRNA bands at higher drug concentration. This was not observed in the samples containing 171 
minocycline. This diffuse fluorescence was subsequently found to be coming from free doxycycline, 172 
as it was not observed when the samples were run without the antibiotics, and became more diffuse 173 
and widespread in antibiotic samples run without dsRNA. This therefore suggests that the 174 
tetracyclines may interact with dsRNA by binding, leaving the unbound drug molecules or molecules 175 
that dissociate from dsRNA to fluoresce above the RNA bands.  176 
 177 
3.3. Effects of tetracycline on dsRNA migration (electrophoretic mobility shift assay) 178 
The observed decrease in dsRNA band intensity in the presence of increasing amounts of the 179 
tetracyclines could result from precipitation of the RNA or differential migration of bound and 180 
unbound dsRNA. This would give rise to smearing of the RNA bands instead of a single/sharp band 181 
that would ordinarily be seen. To eliminate this possibility, gel mobility shift assay was done. The 182 
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results showed no difference in the migration level of the bands from the top of the wells, and no 183 
accumulation of precipitates on the top of the wells (Figure 3A) in the samples containing both 184 
minocycline and doxycycline. These results suggest that the decrease in band intensity of dsRNA 185 
observed with the tetracyclines is not due to changes in the mobility of the complex formed by the 186 
interaction through the gel during electrophoresis. On the other hand, doxycycline was found to 187 
accumulate on the top of the wells at high drug concentrations. Again, this accumulation of drug 188 
molecules on the top of the wells was not observed for minocycline. This further indicates that 189 
doxycycline binds to dsRNA and migrates alongside dsRNA through the gel during electrophoresis, 190 
leaving only the unbound drug molecules at higher concentrations to accumulate in the wells. 191 
To further test the possibility of the tetracyclines binding to dsRNA and keep track of the RNA 192 
molecules while avoiding the complications of interference from drug fluorescence, radioactively-193 
labelled RNA was used. The result showed that the primary dsRNA band intensity remained fairly 194 
consistent (increased slightly with increasing drug concentrations), indicating that the dsRNA is not 195 
precipitated out of the sample during electrophoresis (Figure 3B). This suggests that the earlier 196 
observed decrease in band intensity of FAM-labelled and EtBr-stained dsRNA in the presence of 197 
increasing concentrations of the tetracyclines is not due to loss of RNA during electrophoresis. 198 
However, there was a marked decrease in the intensity of the smaller secondary and tertiary bands 199 
(which are degradation fragments of the radioactively-labelled 27bp dsRNA). This suggests that the 200 
binding of the tetracyclines to dsRNA may protect dsRNA from radioactivity-induced degradation. 201 
The slight increase in band intensity with increasing drug concentration appears to suggest a slightly 202 
higher amount of dsRNA. However, given that the same amount of dsRNA was used in all the 203 
samples, the secondary and tertiary bands with higher intensity at lower drug concentrations may 204 
account for this slight difference. 205 
 206 
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3.4. Tetracycline inhibits binding of nucleic acid ligands to dsRNA 207 
If tetracycline binds to dsRNA, it would be expected to compete with the binding of other molecules 208 
that are known to bind dsRNA. The effect of the interaction of the tetracyclines with dsRNA on the 209 
binding of a known nucleic acid ligand (EtBr) and the relative strength/affinity of the binding of 210 
tetracycline to dsRNA was investigated by adding 1X EtBr (0.5µg/ml) to the sample mixture before 211 
or after the addition of tetracycline. The result showed that the presence of the tetracyclines led to a 212 
dose-dependent decrease in dsRNA band intensity, irrespective of which of the two compounds was 213 
first added to the sample (Figure 4A, B). These results indicate that the tetracyclines reduce the 214 
binding of EtBr to dsRNA, and may be able to displace EtBr bound to dsRNA. Although these 215 
experiments were done with high tetracycline-EtBr molar ratios in the samples (for safety concerns), 216 
the gels were further soaked in EtBr solution to ensure maximum detection of dsRNA bands. After 217 
staining with EtBr, the gels still showed a dose-dependent decrease in band intensity with tetracycline, 218 
suggesting that EtBr is not able to completely displace bound tetracycline from dsRNA. 219 
 220 
To further investigate the nature/mechanism of the binding of tetracycline to dsRNA, a 27bp dsDNA 221 
with a similar base sequence to the 27bp dsRNA was used. As with the dsRNA, a reduction in band 222 
intensity with increasing tetracycline concentrations was also observed. Also, other nucleic acid 223 
ligands were used to stain the gel after electrophoresis in place of EtBr.  Similar results to that of EtBr 224 
were obtained with SYBR Green, SYBR Gold and SYTOX Green staining (Figure 4 C-F). These 225 
results indicate that the tetracyclines bind to dsRNA in a way that is competitive with the binding of 226 
EtBr, SYBR Green, SYBR Gold and SYTOX Green to dsRNA, and similar to the binding of these 227 
ligands to DNA. 228 
3.5. Effects of the interaction with dsRNA on the fluorescence spectra of the 229 
tetracyclines 230 
The absorbance and emission spectra of the tetracyclines were monitored with increasing 231 
concentrations of dsRNA. Again, the presence of Mg
2+
 was found to be essential to generate 232 
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measurable changes in the fluorescence spectra of the drugs, even though it caused a massive 233 
quenching of the fluorescence of both doxycycline and minocycline (>200 folds) and an increase in 234 
the maximum absorption and emission wavelengths (not shown). Therefore, these experiments were 235 
done in Tris buffer (pH 8), with 5mM MgSO4. In these experimental conditions, the maximum 236 
absorption wavelength of doxycycline was found to be 370-375nm, while that of minocycline was 237 
380-385nm (350nm for both without Mg
2+
 in the buffer). The absorbance peak of both drugs was 238 
found to increase slightly (about 8% for doxycycline and 3% for minocycline) upon the addition of 239 
RNA, although a clear dose-response effect was not observed. 240 
The wavelength at which the maximum fluorescence emission was observed for doxycycline and 241 
minocycline was 515nm 410-415nm respectively. The emission peak of doxycycline was found to 242 
decrease with increasing concentrations of dsRNA. On the other hand, the emission peak of 243 
minocycline was found to increase with increasing concentrations of dsRNA (Figure 5A). These 244 
changes are indicative of a binding interaction, and the extent of increase or decrease may be 245 
suggestive of the binding modes (depending on the dye/base pair ratio). These results therefore 246 
suggest that both minocycline and doxycycline bind to dsRNA, but may do so via slightly different 247 
modes such as different degrees of intercalation and surface /groove binding. 248 
3.6. Effects of the interaction with tetracyclines on the circular dichroism (CD) 249 
spectra of dsRNA 250 
The effect of the interaction of the tetracyclines with dsRNA on the dsRNA structure and 251 
conformation was assessed by monitoring the CD spectra of a given concentration of dsRNA (poly 252 
I:C) in the absence and presence of increasing concentrations of minocycline and doxycycline. 253 
Double-stranded poly I:C (50µM) showed a characteristic CD spectrum with two positive bands at 254 
240 and 278 nm respectively, and no negative band. The interaction of both drugs with dsRNA led to 255 
an increase in the positive band wavelength (red shift). With increasing amounts of minocycline (0-256 
50µM), there was an increase in the ellipticity of both positive bands until saturation at 45-50µM 257 
minocycline, with a shift in the wavelength of the bands to 245 and 295 nm respectively (Figure 5B). 258 
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Concomitant with these changes in the intrinsic CD of the dsRNA, two negative bands which also 259 
increased in ellipticity with increasing amounts of minocycline were also observed at 265 and 340 nm 260 
respectively. When titrated with doxycycline, the positive band at 240 nm was no longer observed and 261 
there was a shift in the second positive band from 278 to 290 nm (Figure 5B). The ellipticity of this 262 
positive band also increased with increasing amounts of doxycycline (up to a maximum at 40µM, then 263 
decreased). However, the maximum band intensity was still lower than the intrinsic dsRNA band. In 264 
addition, a negative band with similar characteristic was also observed at 265 nm. These changes in 265 
the CD spectra of the dsRNA molecules upon interaction with minocycline or doxycycline are 266 
suggestive of structural alterations of the dsRNA in complex with the drugs. These results therefore 267 
indicate that the tetracyclines bind to dsRNA to induce structural alterations. They also further 268 
indicate that there may be differences in the specific binding modes of minocycline and doxycycline 269 
respectively to dsRNA. 270 
3.7. Tetracycline inhibits RNase III activity in vitro 271 
In view of the results from the radioactively-labelled RNA (section 3.3), the possibility that the 272 
binding of the tetracyclines to dsRNA could offer some form of protection against degradation and/or 273 
cleavage was assessed by measuring the rate of RNase III degradation of dsRNA in the absence and 274 
presence of increasing amounts of doxycycline. Degradation of the 27bp dsRNA was observed as a 275 
decrease in fluorescence intensity of the band in gel electrophoresis, since it is too short to form 276 
distinct bands of RNase degradation products. Whereas RNA degradation began almost immediately 277 
in the sample without the drug and proceeded quite rapidly, onset of degradation was delayed in the 278 
sample containing doxycycline, and eventually occurred very slowly. Within the time studied in these 279 
experiments (1hr), RNase III degraded only about half of the dsRNA in the sample containing 280 
doxycycline, in contrast to a near complete degradation in the sample without the drug (Figure 6). 281 
Statistical analysis shows that doxycycline significantly reduced the rate of degradation of dsRNA 282 
(multiple regression analysis resulted in p value of 0.001 at 0.05 significance level, R
2
= 0.640). These 283 
results indicate that doxycycline inhibits dsRNA cleavage and degradation by RNase III, suggesting 284 
that doxycycline may interfere with RNase III processing/degradation of dsRNA. However, the 285 
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eventual and slow degradation of dsRNA in the presence of doxycycline suggests that the binding of 286 
the drug to dsRNA may be reversible, and that the enzyme may eventually evade the protective effect 287 
of the drug. 288 
4. DISCUSSION 289 
Different base pairs have been indicated by several studies as the binding site of the tetracyclines to 290 
the 16S ribosomal RNA [14-18]. In view of the variations in these reports as to the exact target site(s), 291 
it is possible that the specific base pairs may not necessarily be the essential targets for the binding of 292 
the tetracyclines to rRNA.  This study therefore investigated the binding of doxycycline and 293 
minocycline to short double-stranded RNAs (seen in most cellular RNAs). The observed decrease in 294 
band intensity of the FAM-labelled dsRNA following electrophoresis in the presence of increasing 295 
amounts of the tetracyclines suggests an interaction with dsRNA. It is possible that the tetracyclines 296 
could quench FAM fluorescence when they interact with the FAM-labelled dsRNA. However, the 297 
observation of similar effect with unlabeled dsRNA stained with EtBr rules out this possibility. It is 298 
also possible that the binding of the tetracyclines to dsRNA could result in precipitation of the RNA, 299 
or a variable degree of mobility shift between bound and unbound dsRNA, as has been reported for 300 
some dsDNA ligands 
26,31
. This would give rise to smearing of the RNA bands instead of a 301 
single/sharp band that would ordinarily be seen. However, neither precipitation nor smearing of RNA 302 
bands was observed in this study. 303 
Mg
2+ 
was suspected to be the critical component of the reaction buffer for an observable effect 304 
because it has been shown to enhance the cross-linking of bases in 30S ribosomal subunit 
32
. The role 305 
of divalent metal ions in the binding of tetracyclines to DNA have been explored by Kohn 
33
, who 306 
noted that little or no tetracycline became bound to DNA in the absence of divalent metal ions, and 307 
magnesium was most effective in enhancing the binding of tetracycline to the nucleic acid. There has 308 
also been speculation that the active drug species that binds to the ribosome is a magnesium-309 
tetracycline complex 
1,34
. Therefore these results concur that divalent cations like Mg
2+
 is an essential 310 
factor in the interaction of the tetracyclines with dsRNA, as the observed effects were enhanced in the 311 
presence of increasing concentrations of Mg
2+
. 312 
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EtBr is used as a stain for nucleic acids because its fluorescence increases several-fold upon binding 313 
(by intercalation) to nucleic acids, allowing detection of the nucleic acids by UV illumination. It then 314 
follows that when more EtBr is bound to a nucleic acid molecule, the band intensity will increase (up 315 
to a saturation point), and vice versa. Therefore, the simplest explanation for the tetracycline effect on 316 
dsRNA band intensity is that the number of dsRNA binding sites available for EtBr binding (used for 317 
staining) was reduced by the presence of tetracycline. In other words, the tetracyclines occupy the 318 
binding sites of EtBr in dsRNA, leaving fewer binding sites available for EtBr during staining. Hence 319 
less EtBr is bound to the dsRNA in the presence of the tetracyclines, which is seen as lower band 320 
intensity for the same concentration of dsRNA. As EtBr is a well characterised nucleic acid ligand, 321 
these observations therefore suggest that the tetracyclines also bind to dsRNA. Again, similar effects 322 
were observed with SYBR Green, SYBR Gold and SYTOX Green. A decrease in fluorescence 323 
intensity has been reported for the binding of SYBR green to dsDNA and total RNA at higher 324 
dye/base pair ratios (dbpr) above the optimal, and this effect was found to be significantly enhanced 325 
by divalent cations 
31
. Since both the nucleic acid stains (dye) and dsRNA were used at the same 326 
concentrations in all the samples in this experiment, the decrease in fluorescence intensity observed 327 
with increasing tetracycline could therefore imply that the presence of tetracycline reduces the number 328 
of base pairs available for the stains to bind, thereby effectively increasing the dye/base pair ratio. The 329 
results of the binding competition assay between doxycycline/minocycline and EtBr indicate that the 330 
tetracyclines not only compete with EtBr for their binding sites on dsRNA, but are able to displace 331 
EtBr from its binding sites in dsRNA. These results therefore suggest that the binding of the 332 
tetracyclines to dsRNA is relatively strong compared to that of EtBr, hence their ability to displace 333 
EtBr from the binding sites on dsRNA and the inability of EtBr to displace the tetracyclines from 334 
dsRNA. They also indicate that the tetracyclines bind to dsRNA in a way that may be similar to the 335 
binding of EtBr, SYBR Green, SYBR Gold and SYTOX Green to DNA; probably by intercalation 336 
and/or electrostatic surface binding, hence their ability to compete with these ligands for binding sites 337 
on the nucleic acids. 338 
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Tetracyclines are naturally fluorescent, and binding to larger molecules such as RNA alter their 339 
fluorescence properties 
35
. The fluorescence intensities of some fluorescent molecules are known to 340 
either increase or decrease upon binding to nucleic acids, depending on factors such as dye/base pair 341 
ratios and the presence of cations 
31,36,37
, as was also observed in this study. It has been reported that 342 
the fluorescence intensity of tetracycline and doxycycline decreases upon binding to DNA, with 343 
doxycycline fluorescence being less quenched than that tetracycline 
28
. In this study however, the 344 
fluorescence intensity of minocycline was found to increase upon interaction with dsRNA while that 345 
of doxycycline decreased. This could be due to differences in the reactive functional groups of the 346 
drugs, which would invariably affect their binding characteristics. Although the fluorescence intensity 347 
of minocycline has been reported to be lower than that of doxycycline 
35
, the huge gap in the 348 
maximum emission wavelength of doxycycline and minocycline (515 and 415 nm respectively) 349 
observed in this study may account for the nearly non-existent fluorescence of minocycline recorded 350 
by Glette et al 
35
 since they only measured emission at 520 nm.  351 
The observed changes in CD spectra of dsRNA upon interaction with the tetracyclines indicate 352 
structural alterations due to binding of the drugs. Increase in ellipticity is a characteristic feature of the 353 
elongation of the duplex as a result of intercalation of the planar molecules between the stacked base 354 
pairs of nucleic acids and subsequent helix opening 
28,38
. Again, the differences in the nature and 355 
magnitude of the CD spectral changes on interaction with minocycline and doxycycline respectively 356 
indicate differences in their binding characteristics, probably due to differences in their reactive 357 
functional groups. 358 
RNase III generally degrades double stranded RNAs both in vitro and in vivo 
39
.  Inhibition of this 359 
process could have wide-ranging implications in living cells. In bacteria, for example, RNase III is 360 
essential for the initial processing of precursor rRNA transcripts for further maturation into the 361 
functional ribosomal RNA necessary for protein synthesis 
40
. In addition to the fact that the viruses 362 
against which the tetracyclines are effective are RNA viruses (West Nile fever virus 
7
, Japanese 363 
encephalitis virus 
18
, human immunodeficiency virus 
19-21
), most viruses produce dsRNA structures 364 
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during replication. This could explicate the mechanism of their wide range of actions against various 365 
microbes. 366 
5. CONCLUSION 367 
This study showed that the tetracyclines (minocycline and doxycycline) bind to short double-stranded 368 
RNAs of random base sequence and inhibit their cleavage by RNase III, indicating that the binding of 369 
the tetracyclines to RNAs may inhibit their processing, and consequently, function. Since the 370 
functional forms of most cellular RNAs often involve secondary and tertiary structures formed by 371 
folding (leading to the formation of short double helices), it is possible that the binding of the 372 
tetracyclines to these double-stranded regions of various cellular RNAs may account for the wide 373 
range of therapeutic effects of the drugs. 374 
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TITLES AND LEGENDS TO FIGURES 472 
1. Figure 1: Effect of the tetracyclines (minocycline and doxycycline) on dsRNA band 473 
intensity. Graphs show decreasing dsRNA band intensity of (A) 200nM siRNA (FAM-474 
labelled dsRNA); (B) 500nM Unlabelled 27bp dsRNA (stained with EtBr after 475 
electrophoresis) with increasing concentrations of minocycline or doxycycline. (C) Band 476 
intensities of various concentrations (0-1000nM) of EtBr-stained 27bp dsRNA (without 477 
tetracycline) compared to 500nM dsRNA in increasing concentrations of 478 
minocycline/doxycycline. (D) A sample gel image (of B). Arrow indicates dsRNA bands, 479 
RFU= Relative fluorescence unit. 480 
2. Figure 2: Effect of Mg2+ on the interaction of the tetracyclines with dsRNA. 481 
Gel image and graphs show decreasing dsRNA band intensity of 200µM FAM-labelled 482 
dsRNA with increasing concentrations of doxycycline, which is enhanced in the presence 483 
of increasing concentrations of Mg2+. Note that the diffuse fluorescence increasing from 484 
left to right above the dsRNA bands in the gel image is from free doxycycline. 485 
3. Figure 3: Effect of the tetracyclines on dsRNA migration through a high resolution gel 486 
(10% native polyacrylamide gel). (A)EtBr-stained gel image shows no difference in gel 487 
shift/mobility of the dsRNA bands in the presence of increasing doxycycline 488 
concentrations, no smearing of the bands and no accumulation of dsRNA precipitates in 489 
the wells. Note the accumulation of free doxycycline may on the top of the last two 490 
wells with high drug concentration. Arrow indicates lane of sample containing the 491 
highest concentration of doxycycline used without dsRNA. (B) Gel and graph of relative 492 
absorbance of radioactively labelled dsRNA in the presence of increasing concentrations 493 
of doxycycline or minocycline. Note that the secondary and tertiary bands are 494 
degradation products of the dsRNA in the primary band. 495 
4. Figure 4: Effect of the tetracyclines on the binding of nucleic acid ligands to dsRNA and 496 
dsDNA: (A,B) Competition assay graphs show decreasing band intensities of 500µM 497 
27bp dsRNA with increasing minocycline/doxycycline concentration in the presence of 498 
1X EtBr, irrespective of which compound was added first to the dsRNA (the tetracyclines 499 
or EtBr); Decreasing band intensities of dsRNA and dsDNA with increasing 500 
concentrations of doxycycline in gels stained with EtBr (C), SYBR green (D), SYBR gold (E) 501 
and SYTOX green (F). 502 
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5. Figure 5: Effects of the interaction of the tetracyclines with dsRNA on the biophysical 503 
properties of the molecules. The graphs show the fluorescence emission spectra (A) of 504 
minocycline and doxycycline in the presence of increasing concentrations of 27bp dsRNA 505 
(excitation wavelength was set at 375nM), and circular dichroism spectra of the dsRNA 506 
(poly I:C) in the presence of increasing concentrations of the drugs (B). For minocycline:  507 
25, 30, 35, 40, 45, 50µM (curves 1-6); for doxycycline:  10, 20, 40, 50µM curves 1-4). M 508 
and D represent the curves for minocycline and doxycycline respectively without any 509 
RNA, R represent CD spectra of 50µMpoly I:C without any drug. 510 
6. Figure 6: Effect of doxycycline on RNase III degradation of dsRNA. Gel image shows (A) 511 
normal degradation of 27bp dsRNA by RNase III (in the absence of tetracycline), (B) 512 
inhibition of degradation in the presence of 1mM doxycycline. Samples were taken from 513 
the reaction mixture at the times (minutes) indicated above each well. The graphs show 514 
the rate of RNase III degradation of dsRNA in the absence (C) and presence (D) of 515 
doxycycline, with a significant difference between the two (p=0.001 at 0.05 significance 516 
level, R2= 0.640). RFU=relative fluorescence unit of dsRNA bands. 517 
 518 
 519 
